CN103446266A - Traditional Chinese medicinal compound preparation for treating type 2 diabetes, and preparation method thereof - Google Patents
Traditional Chinese medicinal compound preparation for treating type 2 diabetes, and preparation method thereof Download PDFInfo
- Publication number
- CN103446266A CN103446266A CN2012101796226A CN201210179622A CN103446266A CN 103446266 A CN103446266 A CN 103446266A CN 2012101796226 A CN2012101796226 A CN 2012101796226A CN 201210179622 A CN201210179622 A CN 201210179622A CN 103446266 A CN103446266 A CN 103446266A
- Authority
- CN
- China
- Prior art keywords
- preparation
- type
- chinese medicinal
- diabetes
- diabetes mellitus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the traditional Chinese medicine field, and concretely discloses a traditional Chinese medicinal compound preparation for treating the type 2 diabetes. The traditional Chinese medicinal compound preparation for treating the type 2 diabetes is prepared through adopting Radix Scutellariae, Rhizoma Coptidis and Radix Puerariae as primary medicines and mixing with auxiliary medicines. The invention also discloses a preparation method of the traditional Chinese medicinal compound preparation for treating the type 2 diabetes. Experiments show that the traditional Chinese medicinal preparation can adjust the glycometabolism of patients suffering from the type 2 diabetes, and can also improve the islet beta cell functions of the patients. The preparation can well treat the type 2 diabetes, and has the advantages of small dosage, appropriate price, safety and effectiveness after long-term taking, and good patient evaluation.
Description
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to a kind of compound Chinese medicinal preparation for the treatment of type 2 diabetes mellitus and preparation method thereof.
Background technology
Type 2 diabetes mellitus is the disease of a kind of lifelong existence slow progress, and its pathogenic process is: NGT → IGR → type 2 diabetes mellitus, the key link of morbidity is insulin resistant and islet beta cell function defect.Insulin resistant is applied in type 2 diabetes mellitus and occurs, develops all the time, and β cell function defect is the essential condition of its morbidity.In fact, 50% there is insulin resistant nearly in the crowd.But the incidence rate of diabetes is not parallel with insulin resistant, this is because the β cell can descend blood glucose by the compensatory excreting insulin.All type 2 diabetes mellitus patients all have the β cell function impaired.The result of study of Pima American Indian shows, in oral glucose tolerance test, lower (IGT) individuality again to diabetics from Normal glucose tolerance (NGT) is individual to glucose tolerance, its insulin secretion level descends successively, especially type 2 diabetes mellitus patient, its First-phase insulin secretion disappearance.The islet beta cell function obstacle is that the core of type 2 diabetes mellitus is abnormal.
The major diseases such as type 2 diabetes mellitus and coronary heart disease, cerebrovascular, tumor are in close relations, and along with the prolongation of the course of disease, its chronic complicating diseases day by day aggravates, and has caused huge burden on society and financial burden.Modern medicine proves, above-mentioned these harm are closely related with the islet beta cell function degree of injury.Although there are many medicines to come out, comprise multiple insulin substitution product, authority's the evidence-based medicals such as UKPDS, DCCT all show, no matter take which kind of medicine (comprising insulin), along with the course of disease extends, islet beta cell function descends day by day, and with the generation positive correlation of complication.Therefore, improve islet beta cell function, improving the insulin secretion level is the key link of preventing and treating diabetes.
Type 2 diabetes mellitus belongs to Chinese medicine " diabetes " category, take yin asthenia generating intrinsic heat as the core pathogenesis, adopt there is yin nourishing, the treatment by Chinese herbs primary disease of heat clearing away, the kidney invigorating, the effect such as soothing the liver.Although the research and comparison of domestic this respect is abundant, marketed drug is also arranged, but still Shortcomings.For example, most Chinese medicine compound are improving patient's symptom as the curative effect index, limited on the impact of blood glucose; The Chinese patent medicine flavour of a drug that partly go on the market are lengthy and jumbled, and day taking dose is bigger than normal; The Chinese patent medicine flavour of a drug that partly go on the market are simplified, but expensive, are unfavorable for promoting.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of new Chinese medicine of safe and effective, dosing is less, price is appropriate treatment type 2 diabetes mellitus, is specifically related to a kind of compound Chinese medicinal preparation for the treatment of type 2 diabetes mellitus.For this reason, the present invention also provides the preparation method of the compound Chinese medicinal preparation of this treatment type 2 diabetes mellitus.
For solving the problems of the technologies described above, the invention provides a kind of compound Chinese medicinal preparation for the treatment of type 2 diabetes mellitus, it is to be made by effective ingredient and pharmaceutic adjuvant, described effective ingredient is made by the crude drug of following weight portion: Rhizoma Coptidis 1-2 part, 34 parts of Radix Scutellariaes, Radix Puerariae 5-7 part are preferably: 2 parts of Rhizoma Coptidis, 3 parts of Radix Scutellariaes, 6 parts of Radix Puerariaes.
Described effective ingredient is berberine, baicalin and puerarin.Preferably, the percentage by weight of described berberine in this Chinese medicine preparation is 15.02%; The percentage by weight of described baicalin in this Chinese medicine preparation is 22.2%; The percentage by weight of described puerarin in this Chinese medicine preparation is 7.5%.
Crude drug Rhizoma Coptidis, Radix Scutellariae and Radix Puerariae involved in the present invention recorded Chinese medicine by Chinese Pharmacopoeia one one of version in 2000, and meets the pharmacopeia prescription.
The present invention can adopt the pharmaceutic adjuvant of this area routine and the common process method of Chinese medicine preparation to be prepared into any this area oral preparations commonly used, such as water decoction, granule, capsule, the prepared slices of Chinese crude drugs, tablet etc.
The present invention can adopt the preparation process of various routines, adds molding adjuvant or taste masking adjuvant, granulation agent medicine dosage form.For this reason, the invention provides a kind of preparation method for the treatment of the Chinese native medicine compound prescription pellet agent of type 2 diabetes mellitus, comprise the steps:
Get half amount of above-mentioned formula ratio crude drug, add water 3-8 and doubly measure, after soaking half an hour, decoct 45min, then add water 3-8 and doubly measure, decoct 30min, filter, merge decoction liquor, concentrating under reduced pressure, drying under reduced pressure obtains dry extract, is ground into fine powder (crossing 80 orders).Second half crude drug was pulverized 80 orders, with CO60 sterilizing (irradiation dose 8k), mixed with extract powder, added pharmaceutic adjuvant, after mix homogeneously with 60～70% ethanol as the binding agent granulation.Described pharmaceutic adjuvant can be selected from mannitol, lactose, cane sugar powder, magnesium stearate, aspartame, any one or a few in Mentholum and oleum Citri sinensis essence.
Beneficial effect of the present invention is: Chinese medicine preparation of the present invention is by clinical trial, the regulating action that proof is useful to type 2 diabetes mellitus patient carbohydrate metabolism (representing the golden index HbA1c of patient's blood sugar level ↓ decline), improve the effect (the key index HOMA2%B of clinical evaluation diabetics islet function ↑ rising) of patient's islet beta cell function.Chinese medicine preparation of the present invention is by zoopery, prove that it can reduce the blood glucose of diabetes model rat, improve beta cells of isolated rat islets function (serum insulin concentration of reflection rat excreting insulin ability ↑ risings represents the key factor PDX-1 that beta Cell of islet regenerates ↑ rising).Above-mentionedly experimental results show that Chinese medicine preparation of the present invention can effectively treat type 2 diabetes mellitus, dosing is less, price is appropriate, and long-term taking is safe and effective, and the patient assessment is good.
The accompanying drawing explanation
Figure 1A-Fig. 1 C be in embodiment 1 Chinese medicine preparation of the present invention to the glycometabolic regulating action schematic diagram of type 2 diabetes mellitus patient; Wherein, Figure 1A is the variation schematic diagram of FPG; Figure 1B is the variation schematic diagram of PPG; Fig. 1 C is the variation schematic diagram of HbA1c;
Fig. 2 is the effect schematic diagram of Chinese medicine preparation of the present invention to type 2 diabetes mellitus patient islet beta cell function in embodiment 2;
Fig. 3 is the blood sugar reducing function schematic diagram of Chinese medicine preparation of the present invention to the diabetes model rat in embodiment 3, in Fig. 3, and one factor analysis of variance F=151.7, P<0.01; Between group, relatively adopt in twos tamhane to analyze, P<0.01.
The specific embodiment
Below by Preparation Example, the invention will be further elaborated:
Weighting raw materials: Rhizoma Coptidis 6 grams, Radix Scutellariae 9g, Radix Puerariae 18 grams.
Preparation process: get half amount of above-mentioned raw materials medicine, add 3 times of amounts of water, after soaking half an hour, decoct 45min, then add 3 times of amounts of water, decoct 30min, filter, merge decoction liquor, concentrating under reduced pressure, drying under reduced pressure obtains dry extract, is ground into fine powder (crossing 80 orders).Second half crude drug was pulverized 80 orders, with CO60 sterilizing (irradiation dose 8k), mixed with extract powder, added mannitol, lactose, cane sugar powder, aspartame, Mentholum, after mix homogeneously with 60% ethanol as the agent of binding agent granulation.Granule is the 5g/ bag, oral 2 times of every day, each 1 bag.
Embodiment 2 granules
Weighting raw materials: Rhizoma Coptidis 3 grams, Radix Scutellariae 9g, Radix Puerariae 15 grams.
Preparation process: get half amount of above-mentioned raw materials medicine, add 8 times of amounts of water, after soaking half an hour, decoct 45min, then add 8 times of amounts of water, decoct 30min, filter, merge decoction liquor, concentrating under reduced pressure, drying under reduced pressure obtains dry extract, is ground into fine powder (crossing 80 orders).Second half crude drug was pulverized 80 orders, with CO60 sterilizing (irradiation dose 8k), mixed with extract powder, added mannitol, lactose, cane sugar powder, aspartame, Mentholum, after mix homogeneously with 70% ethanol as the agent of binding agent granulation.Granule is the 5g/ bag, oral 2 times of every day, each 1 bag.
Embodiment 3 granules
Weighting raw materials: Rhizoma Coptidis 6 grams, Radix Scutellariae 12g, Radix Puerariae 21 grams.
Preparation process: get half amount of above-mentioned raw materials medicine, add 5 times of amounts of water, after soaking half an hour, decoct 45min, then add 5 times of amounts of water, decoct 30min, filter, merge decoction liquor, concentrating under reduced pressure, drying under reduced pressure obtains dry extract, is ground into fine powder (crossing 80 orders).Second half crude drug was pulverized 80 orders, with CO60 sterilizing (irradiation dose 8k), mixed with extract powder, added mannitol, lactose, cane sugar powder, aspartame, Mentholum, after mix homogeneously with 65% ethanol as the agent of binding agent granulation.Granule is the 5g/ bag, oral 2 times of every day, each 1 bag.
Embodiment 4 prepared slices of Chinese crude drugs
Weighting raw materials: Rhizoma Coptidis 6 grams, Radix Scutellariae 10g, Radix Puerariae 20 grams.
Crude drug is placed in container and uses the distilled water submergence, approximately 120 minutes.Adding distil water makes volume enlarge approximately 8～10 times, heats and boils, and continues about 30 minutes.Get filtrate, be placed on clean containers for future use.Adding distil water, make volume enlarge approximately 8～10 times again, heats and boil, and continues about 30 minutes.Get filtrate, twice filtrate is merged, heat and make filtrate be concentrated into the 2000ml left and right.Gradation is centrifugal by filtrate, and speed controlling, at 2500r/min, approximately 30 minutes, is got supernatant.Merge supernatant, again boil 30 minutes, decoct concentration is adjusted to every milliliter of concentrated solution containing crude drug 3g, the packing filling bottle, standby; 200 milliliters every bottle, oral secondary,, can add appropriate warm water and take bottle by each 6 milliliters every day.
Embodiment 5 water decoctions
Weighting raw materials: Rhizoma Coptidis 6 grams, Radix Scutellariae 10g, Radix Puerariae 20 grams.
By the medicinal water boiling and extraction of above-mentioned raw materials 2 times, decoct and add water 1200ml for the first time, decocting time is 40 minutes, gets residue juice 150ml, decocts and adds water 700ml for the second time, decocting time is 35 minutes, gets residue juice 150ml, every day oral secondary, each 150ml.
Below example is further elaborated beneficial effect of the present invention by experiment:
Experimental example 1 Chinese medicine preparation of the present invention is to the glycometabolic regulating action of type 2 diabetes mellitus patient
1. research method: adopt the method for random, double blinding, placebo to be studied.
1. random method: the object of study that meets inclusive criteria is adopted to the table of random number method, in 1:1 ratio random packet.At first work out case random assortment table, according to case random assortment table, obtain the clinical research random number, include respectively A, B group in.
2. sample content: the maturity-onset diabetes prevalence is about 5.5% at present, according to the practical situation of this research, intends carrying out the small sample clinical research, each 30 routine patients for the treatment of group and matched group.Consider tear-away factor, then increase by 20% sample size.Selected 36 pairs of final design, totally 72 routine clinical cases.
3. blind method design: this research adopts the double blind control method, Chinese medicine preparation of the present invention and control drug thereof (adopt placebo in this clinical trial, the manufacture method of placebo is that the preparation of the present invention of 1/10th concentration adds adjuvant, does not adopt other Chinese medicine preparation) by Jiangyin Tian Jiang Pharma Inc., be responsible for making and packing.According to double blind standardized operation step, investigational agent and contrast medicine are repacked and distributed, comprise emergent mail etc.
2. case system of selection
2.1 inclusive criteria: 1) allly meet the patient that diabetes diagnosis standard and typing belong to type 2 diabetes mellitus; 2) glycolated hemoglobin<10%; 3) blood pressure≤150/90mmHg; 4) and sign the Informed Consent Form person can include the experiment case in.
2.2 exclusion standard: 1) age is at under-18s or more than 70 years old; 2) gestation or women breast-feeding their children; 3) complication such as severe cardiac, liver, kidney are arranged, or be associated with other serious primary diseases, the psychotic; 4) existing macrovascular complications, as myocardial infarction, cerebrovascular accident, vascular change at lower extremities occurred; 5) in nearly January, the seriously ill critical disease of glycosuria appears, as ketoacidosis, Diabetic hyperosmolar; 6) to related drugs allergy in therapeutic scheme, the person that is not suitable for accepting this therapeutic scheme.
2.3 the rejecting of case and coming off: all cases that does not meet inclusive criteria and included in by mistake; Though meet inclusive criteria but the case of medication not after including in; Experimental session is to this observation related drugs allergy sufferers.Experimenter's compliance is poor, serious adverse events occurs, severe complication or special physiological occur changes and should not continue reception test, and the case of medication etc. in accordance with regulations, be not the case that comes off.Should process in conjunction with practical situation during statistical analysis, as untoward reaction person occurs, should add up by untoward reaction.Completed 1/2 the course for the treatment of, should add up curative effect.
3. therapeutic scheme
3.1 Primary Care: 1. maintain original blood sugar lowering scheme; 2. complicated hypertension person depressor comprises: calcium ion antagonist (CCB), diuretic, beta-blocker, α receptor blocking agent; If any using the ACEI(angiotensin converting enzyme inhibitor), the ARB(angiotensin receptor blocker) class medicine person, needing to stop using can enter group more than two weeks; 3. life style intervention.
3.2 drug combination: except above-mentioned Primary Care medication, viewing duration bans use of other Chinese medicine relevant to treating diabetes, and Ta Ting or fibrate lipid-lowering medicine need drug withdrawal can enter group more than two weeks.
3.3 GP TH: treatment group gives Chinese medicine preparation of the present invention, every day twice, one bag of every day.Matched group gives all consistent placebo (adopt placebo in this clinical trial, the manufacture method of placebo is that the preparation of the present invention of 1/10th concentration adds adjuvant, does not adopt other Chinese medicine preparation) of appearance packaging, every day twice, one bag of every day.
3.4 course for the treatment of and following up a case by regular visits to: be decided to be 12 weeks the course for the treatment of.Each month is followed up a case by regular visits to once, measures fasting glucose, 2 hours blood glucoses, blood pressure, Body Mass Index, waist-to-hipratio after the meal at every turn.
4. ethics requirement and experimenter's informed consent: this clinical trial must be followed Declaration of Helsinki (version in 2000) and carry out with Chinese relevant clinical experimental study standard, rules.Before on-test, by Ethics Committee of our unit, agreed can implement this testing program after this testing program.Before each this research of subject enrollment, the research doctor has a responsibility for written written form, to itself or its appointment, represents complete, as to introduce all sidedly this research purpose, program and possible risk.Should allow the patient know their this research of having the right to exit at any time.Before selected, must give every experimenter a written patient's Informed Consent Form.
Observed result (in Table 1 and Figure 1A-Fig. 1 C):
Table 1. metabolism of blood glucose
* variance analysis, F=4.153, P=0.044
As data show in table 1 and Figure 1A-Fig. 1 C, Chinese drug-treated group (taking Chinese medicine preparation of the present invention) HbA1c descends, and placebo group (taking control drug) HbA1c changes not obvious, illustrates that Chinese medicine preparation of the present invention has certain blood sugar reducing function.From data, the decline degree of Chinese drug-treated group FPG and PPG all is greater than placebo group (placebo group FPG rises after intervening).
The effect of experimental example 2 Chinese medicine preparation of the present invention to type 2 diabetes mellitus patient islets of langerhans β function
The contents such as research design method, case system of selection, therapeutic scheme, ethics design are with experimental example 1.
Observed result is in Table 2 and Fig. 2.
Table 2. islet cell function changes (HOMA2 index)
* variance analysis, F=5.949, P=0.016
As data show in table 2 and Fig. 2, Chinese drug-treated group (taking Chinese medicine preparation of the present invention) HOMA2%B index rises, and placebo group (taking control drug) HOMA2%B changes not obvious, illustrates that Chinese medicine preparation of the present invention has the effect that improves islet beta cell function.In addition, from data, Chinese drug-treated group HOMA2%S rises, and HOMA2%IR descends, and variation tendency and degree all are better than placebo group.
Experimental example 3 Chinese medicine preparation of the present invention reduces the effect of blood glucose in diabetic rats
1. materials and methods:
1.1 Experimental agents: Chinese medicine preparation of the present invention.
1.2 modeling method: healthy male Wistar rat (2 week age), after adaptability is fed 1 week, feed the compound of high lipid food and normal feedstuff, change complete high lipid food after 2 weeks into, after feeding 6 weeks, lumbar injection streptozotocin (25mg/kg body weight), continue to feed high lipid food, blood glucose is surveyed in the docking blood sampling after 4 weeks, selects pathoglycemia person's (blood glucose > 16.7mmol/L) to continue to feed high lipid food 2 weeks, enters grouping experiment after checking blood glucose.Laboratory animal, the high lipid food of normal feedstuff and customization provides by Chinese Academy of Sciences's Shanghai Experimental Animal Center.
1.3 experimental procedure: 1., after type 2 diabetes mellitus rat modeling success, the near rat of selective body heavy phase starts experiment.Whole experimental session, all rats all give normal feedstuff.2. adopt the table of random number method, rat is divided into to 3 groups (Chinese drug-treated group (using Chinese medicine preparation of the present invention)/model group (using normal saline)/GLP-1 groups (using the GLP-1 analog)), gavage, once a day; It is radix that rat dose every day be take human body dosage every day by per kilogram of body weight, according to conversion coefficient, is calculated (conversion coefficient is defined as 15).3. record weekly the Growth in Rats situation once.4. intervention time is 4 weeks.5. choose at random 20 of rats for every group, after fasting 12h, with 3% pentobarbital sodium (40mg/kg) intraperitoneal injection of anesthesia.6. respectively at rat 0min with gavage 5min after glucose load (2g/kg), 10min, the 15min time point is got each 1ml of whole blood, according to test kit, requires collecting sample, separation of serum ,-70 ℃ of cryogenic refrigerators are preserved, the unified index of correlation that detects.7. choose at random 10 of rats for every group, after fasting 12h, with 3% pentobarbital sodium (40mg/kg) intraperitoneal injection of anesthesia, Isolation of pancreatic, liquid nitrogen container is preserved.Detecting PDX-1 after homogenate expresses.
1.4 observation index: rat blood sugar detects PDX-1 factors check (RT-PCR method) in (Roche Advandge) islet cells, and serum insulin detects (Elisa method).
2. experimental result:
Table 3 is respectively organized glucose tolerance test result (x ± s, the mmol/L of blood glucose unit)
Illustrate: * represents that 3 groups of blood glucose of each time point relatively adopt one factor analysis of variance P<0.01; Between group, compare in twos, 30min and 60min time point blood glucose adopt the LSD check, and 0min and 120min time point blood glucose adopt the Tamhane check; △ represents the vs Chinese drug-treated group, P<0.05; ▲ represent vs GLP-1 group, P<0.05; Zero represents vs GLP-1 group, P<0.05.
As shown in table 3 and Fig. 3, by comparing the blood glucose of 3 groups of each time points of rat carbohydrate tolerance, although we find that the blood sugar reducing function of Chinese medicine preparation of the present invention, not as GLP-1, exists really.Utilize area computing formula under glucose curve (AUCg=1/4 (G0min+G30min)+1/4 (G30min+G60min)+1/2 (G60min+G120min)), again affirmed the blood sugar reducing function of Chinese medicine preparation of the present invention, see Fig. 3.
Experimental example 4 Chinese medicine preparation of the present invention improves the effect of diabetes rat islet beta cell function
Materials and methods with experimental example 3(slightly)
Experimental result is in Table 4 and table 5:
Table 4 is respectively organized rat insulin concentration change (x ± s, the pM of unit)
Illustrate: * represents that 3 groups of Insulin of each time point relatively adopt one factor analysis of variance P<0.01; Between group, compare in twos, 5min time point insulin adopts the LSD check, and its excess-three time point blood glucose adopts the Tamhane check; △ represents the vs Chinese drug-treated group, P<0.05; ▲ represent vs GLP-1 group, P<0.05; Zero represents vs GLP-1 group, P<0.05.
Table 5 is respectively organized the variation (getting the Lg value, ± s) of P of Rats DX-1 factor expression
Illustrate: * represents that 3 groups relatively adopt one factor analysis of variance P<0.01; Compare in twos between group, adopt the LSD check;
△ represents vs spleen invigorating Qinghua side group, P<0.05; ▲ represent vs GLP-1 group, P<0.05; Zero represents vs GLP-1 group, P<0.05.
In above-mentioned table 4 and table 5, we can clearly see, although Chinese drug-treated group rat blood serum insulin concentration, lower than Western medicine GLP-1 group, but still apparently higher than model group, illustrates its blood sugar lowering curative effect and to promote that insulin discharges relevant.Between three groups, there are notable difference in Proinsulin and PDX-1 gene expression; Comparative result in twos between group, compare with model group, and Chinese drug-treated group and GLP-1 group PDX-1 be all apparently higher than model group, and Chinese drug-treated group and GLP-1 group difference not obvious (P > 0.05); Although Chinese drug-treated group Proinsulin measured value, higher than model group, does not have significant difference, GLP-1 group Proinsulin expresses apparently higher than other two groups.
Comprehensive above-mentioned experimental result, can prove that Chinese medicine preparation of the present invention can improve the expression of PDX-1 gene in islets of langerhans, improves islet beta cell function, promotes that insulin is released into blood, reduces rat blood sugar.
Claims (6)
1. a compound Chinese medicinal preparation for the treatment of type 2 diabetes mellitus, it is to be made by effective ingredient and pharmaceutic adjuvant, it is characterized in that, described effective ingredient is made by the crude drug of following weight portion: Rhizoma Coptidis 1-2 part, Radix Scutellariae 3-4 part, Radix Puerariae 5-7 part.
2. by the compound Chinese medicinal preparation for the treatment of type 2 diabetes mellitus claimed in claim 1, it is characterized in that, described effective ingredient is made by the crude drug of following weight portion: 2 parts of Rhizoma Coptidis, 3 parts of Radix Scutellariaes, 6 parts of Radix Puerariaes.
3. by the compound Chinese medicinal preparation of the described treatment type 2 diabetes mellitus of claim 1 or 2, it is characterized in that, described effective ingredient is berberine, baicalin and puerarin.
4. by the compound Chinese medicinal preparation for the treatment of type 2 diabetes mellitus claimed in claim 3, it is characterized in that, the percentage by weight of described berberine in this Chinese medicine preparation is 15.02%; The percentage by weight of described baicalin in this Chinese medicine preparation is 22.2%; The percentage by weight of described puerarin in this Chinese medicine preparation is 7.5%.
5. the preparation method by the compound Chinese medicinal preparation of the described treatment type 2 diabetes mellitus of claim 1-4 any one, is characterized in that, comprises the steps:
The weighting profit requires half amount of 1 described crude drug, adds water 3-8 and doubly measures, and after soaking half an hour, decocts 45min, then adds water 3-8 and doubly measure, and decocts 30min, filters, merges decoction liquor, concentrating under reduced pressure, and drying under reduced pressure obtains dry extract, is ground into fine powder; Second half crude drug was pulverized 80 orders, used the CO60 sterilizing, mixed with extract powder, added pharmaceutic adjuvant, after mix homogeneously with 60～70% ethanol as the binding agent granulation.
6. by preparation method claimed in claim 5, it is characterized in that, described pharmaceutic adjuvant is selected from mannitol, lactose, cane sugar powder, magnesium stearate, aspartame, any one or a few in Mentholum and oleum Citri sinensis essence.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101796226A CN103446266A (en) | 2012-06-01 | 2012-06-01 | Traditional Chinese medicinal compound preparation for treating type 2 diabetes, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101796226A CN103446266A (en) | 2012-06-01 | 2012-06-01 | Traditional Chinese medicinal compound preparation for treating type 2 diabetes, and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103446266A true CN103446266A (en) | 2013-12-18 |
Family
ID=49729379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101796226A Pending CN103446266A (en) | 2012-06-01 | 2012-06-01 | Traditional Chinese medicinal compound preparation for treating type 2 diabetes, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103446266A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104107324A (en) * | 2014-07-29 | 2014-10-22 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine compound preparation for treating type II diabetes mellitus and preparation method of traditional Chinese medicine compound preparation |
| CN106074753A (en) * | 2016-06-16 | 2016-11-09 | 上海中医药大学附属曙光医院 | Promote Chinese herbal compounds of glucagon-like peptide 1 secretion and preparation method thereof |
| CN106138861A (en) * | 2015-04-05 | 2016-11-23 | 云南云百草实验室有限公司 | A kind of Chinese medicine treating type-II diabetes and preparation method thereof |
| CN108619264A (en) * | 2017-03-17 | 2018-10-09 | 西南医科大学 | One seed ginseng yellow capsule and its preparation process |
-
2012
- 2012-06-01 CN CN2012101796226A patent/CN103446266A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 陶枫等: "清化方改善代谢综合征人群氧化应激水平的临床研究", 《时珍国医国药》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104107324A (en) * | 2014-07-29 | 2014-10-22 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine compound preparation for treating type II diabetes mellitus and preparation method of traditional Chinese medicine compound preparation |
| CN106138861A (en) * | 2015-04-05 | 2016-11-23 | 云南云百草实验室有限公司 | A kind of Chinese medicine treating type-II diabetes and preparation method thereof |
| CN106074753A (en) * | 2016-06-16 | 2016-11-09 | 上海中医药大学附属曙光医院 | Promote Chinese herbal compounds of glucagon-like peptide 1 secretion and preparation method thereof |
| CN108619264A (en) * | 2017-03-17 | 2018-10-09 | 西南医科大学 | One seed ginseng yellow capsule and its preparation process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101890125B (en) | Medicament for treating hyperthyroidism and preparation method thereof | |
| CN101612316B (en) | Application of dendrobium officinale aqueous extract in preparing medicine for preventing and treating hypertension and apoplexy | |
| CN109549971A (en) | A kind of functional food and preparation method thereof adjusting hyperglycemia | |
| CN104107324A (en) | Traditional Chinese medicine compound preparation for treating type II diabetes mellitus and preparation method of traditional Chinese medicine compound preparation | |
| CN103446266A (en) | Traditional Chinese medicinal compound preparation for treating type 2 diabetes, and preparation method thereof | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN101513492A (en) | Chinese medicament for treating diabetes | |
| CN103417846A (en) | Hypoglycemic traditional Chinese medicine composition and preparation method thereof | |
| CN103191298A (en) | Traditional Chinese medicinal composition for treating blood group incompatibility haemolytic disease and preparation method thereof | |
| CN101108225A (en) | Diabetes treating capsule dose and technique of preparing the same | |
| CN104815166A (en) | Traditional Chinese medicine composition for treating diabetes as well as preparation and application of traditional Chinese medicine composition | |
| CN108403818B (en) | Composition for assisting in reducing blood sugar and application thereof | |
| CN102940800A (en) | Traditional Chinese medicine for treating diabetes | |
| CN103211996B (en) | Preparation method of traditional Chinese medicine for treating diabetes mellitus | |
| CN102335249B (en) | Oral capsule for treating II-type diabetes | |
| CN106214787B (en) | A kind of Chinese medicine composition for treating diabetes and preparation method thereof and purposes | |
| CN108042710B (en) | Traditional Chinese medicine composition for treating qi-yin deficiency and damp-heat internal accumulation type 2 diabetes and application thereof | |
| CN104605051B (en) | Double numb tea containing leaves of Eucommia ulmoides and preparation method | |
| CN103230552B (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN100571729C (en) | The migrainous Chinese medicine of a kind of treatment | |
| CN102743461A (en) | Traditional Chinese medicine composition capable of harmonizing stomach and soothing the nerves and preparing method and application thereof | |
| CN104042928B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN101537102A (en) | Medical and edible dual-purpose composition for treating sugar diabetes and preparation method thereof | |
| CN100509019C (en) | Application of Baji capsule in preparing immune enhancement medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131218 |